Tag: European Commission
Biocon Biologics receives MHRA, UK approval for YESAFILI, a biosimilar of...
In September, YESAFILI®, received marketing authorization approval from the European Commission (EC) for the European Union (EU)
BSV to set up a new biopharma manufacturing plant in Genome...
Proposed bio-pharmaceutical manufacturing facility will cater to domestic and export markets including regulated markets like USA and EU
Biocon Biologics receives European Commission approval for YESAFILI biosimilar Aflibercept
Aflibercept had EU brand sales of approximately $1.8B for the 12 months ending December 31, 2022, according to IQVIA
Biocon Biologics announces positive CHMP opinion for its biosimilar to treat...
The CHMP positive opinion will be considered by the European Commission whose decision on the approval is expected by the end of September 2023